Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.60 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666626 | 1.00 | CXCR2 (0.60) | CXCR2CXCR1CA2CA1CA9 | |
| SCHEMBL4414662 | 0.82 | CXCR2 (0.66) | CXCR2CXCR1CA2CA1CA9 | |
| SCHEMBL252024 | 0.82 | CXCR2 (0.66) | CXCR2CXCR1CA2CA1CA9 | |
| SCHEMBL1345636 | 0.82 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL1820095 | 0.82 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL245190 | 0.82 | CXCR2 (0.69) | CXCR2CXCR1 | |
| SCHEMBL4747670 | 0.80 | CXCR2 (0.66) | CXCR2CXCR1CA2CA1CA9 | |
| SCHEMBL246051 | 0.80 | CXCR2 (0.66) | CXCR2CXCR1CA2CA1CA9 | |
| SCHEMBL1821726 | 0.79 | CXCR2 (0.61) | CXCR2CXCR1STSDRD2DRD1 | |
| SCHEMBL28065258 | 0.79 | CXCR2 (0.69) | CXCR2CXCR1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2019-08-15 | — | — | US | claimed |
| US-9556115-B2 | Sulfonamides for the prevention of diabetes | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-01-31 | — | — | US | claimed |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | NEW YORK UNIVERSITY | 2016-06-16 | — | — | US | claimed |
| EP-3011012-A2 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | New York University (US) | 2016-04-27 | — | — | EP | claimed |
| EP-2485724-B1 | Sulfonamides for the prevention of diabetes | DOMPÉ FARMACEUTICI S P A (IT) | 2016-02-10 | — | — | EP | claimed |
| US-20150011639-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2015-01-08 | — | — | US | claimed |
| WO-2014205127-A2 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | NEW YORK UNIVERSITY (US) | 2014-12-24 | — | — | WO | claimed |
| US-8846755-B2 | Sulfonamides for the prevention of diabetes | Dompé S.p.A. (IT) | 2014-09-30 | — | — | US | claimed |
| EP-2485723-B1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | DOMPE SPA (IT) | 2013-12-11 | — | — | EP | claimed |
| US-20130059908-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | DOMPE' S.P.A. (IT) | 2013-03-07 | — | — | US | claimed |
| EP-2485723-A1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | Dompé S.p.A. (IT) | 2012-08-15 | — | — | EP | claimed |
| EP-2485724-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | Dompé S.p.A. (IT) | 2012-08-15 | — | — | EP | claimed |
| US-20120202884-A1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | DOMPE' S.P.A. (IT) | 2012-08-09 | — | — | US | claimed |
| WO-2011042465-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | Dompé S.p.A. (IT) | 2011-04-14 | — | — | WO | claimed |
| WO-2011042466-A1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | Dompé S.p.A. (IT) | 2011-04-14 | — | — | WO | claimed |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | NEW YORK UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | UNIV NEW YORK (US) | 2023-05-18 | — | — | US | disclosed |
| EP-2485724-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | Dompé S.p.A. (IT) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202884-A1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | DOMPE' S.P.A. (IT) | 2012-08-09 | — | — | US | disclosed |
| WO-2011042465-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | Dompé S.p.A. (IT) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202884-A1 | INHIBITORS OF CXCR1/2 AS ADJUVANTS IN THE TRANSPLANT OF PANCREATIC ISLETS | CXCR1, CXCR5, CXCR2 | CXCR2 3/4885CXCR1 1/4885CA2 2329/4885 |
| US-20150011639-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | SULT1A1, SULT2A1, SUCNR1 | CXCR2 3767/4885CXCR1 1817/4885CA2 1344/4885 |
| US-20230151081-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CA2 3642/4885 |
| US-11932683-B2 | Cellular factors involved in the cytotoxicity of Staphylococcus aureus leukocidins: novel therapeutic targets | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CA2 3642/4885 |
| US-20190248876-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CA2 3642/4885 |
| US-20130059908-A1 | SULFONAMIDES FOR THE PREVENTION OF DIABETES | SULT1A1, SULT2A1, SUCNR1 | CXCR2 3767/4885CXCR1 1817/4885CA2 1344/4885 |
| US-20160168233-A1 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS | CXCR1, CXCR2, CXCR5 | CXCR2 2/4885CXCR1 1/4885CA2 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.